



Blood-based circulating biomarkers for prediction of immune-checkpoint inhibitors efficacy in renal cell carcinoma

Loubna Omri^{1,2}, Marie Naigeon^{3,4}, Ronan Flippot^{3,5}, Javier Gavira-Díaz⁵, Jesus Poveda-Ferriols^{2,6}, Dan Nguyen², Chaimae Abdi¹, Alvaro Arroyo-Salgado², Nathalie Chaput³, Guillermo de Velasco⁷, Laurence Albigès^{3,5}, Lucía Carril-Ajuria^{2,6*}

¹Department of Medical Oncology, National Institute of Oncology, Rabat X4FH+66, Morocco

²Medical Oncology Department, Centre Hospitalier Universitaire Brugmann, 1020 Brussels, Belgium

³Laboratory of Immunomonitoring in Oncology, Gustave Roussy, 94805 Villejuif, France

⁴Paris-Saclay University, School of Pharmacy, 91190 Orsay, France

⁵Medical Oncology Department, Institut Gustave Roussy, 94805 Villejuif, France

⁶Medical Oncology Department, Centre Hospitalier Universitaire Saint-Pierre, 1000 Brussels, Belgium

⁷Medical Oncology Department, University Hospital 12 de Octubre, 28041 Madrid, Spain

***Correspondence:** Lucía Carril-Ajuria, Medical Oncology Department, Centre Hospitalier Universitaire Saint-Pierre, 1000 Brussels, Belgium. carrilajuria.lucia@gmail.com

Academic Editor: Eyad Elkord, University of Salford, UK

Received: June 17, 2024 **Accepted:** August 9, 2024 **Published:** September 20, 2024

Cite this article: Omri L, Naigeon M, Flippot R, Gavira-Díaz J, Poveda-Ferriols J, Nguyen D, et al. Blood-based circulating biomarkers for prediction of immune-checkpoint inhibitors efficacy in renal cell carcinoma. *Explor Target Antitumor Ther.* 2024;5:1199–222. <https://doi.org/10.37349/etat.2024.00271>

Abstract

Immune checkpoint inhibitors (ICI)-based combinations have become the standard first-line treatment for advanced clear cell renal cell carcinoma (ccRCC). Despite significant improvements in survival and the achievement of sustained long-term responses, a subset of patients remains refractory to ICI, and most will eventually develop resistance. Thus, identifying predictive biomarkers for ICI efficacy and resistance is essential for optimizing therapeutic strategies. Up to now, tissue-based biomarkers have not been successful as predictive biomarkers in RCC. Circulating blood-based biomarkers offer a promising alternative. These biomarkers, including circulating immune cells, soluble factors, tumor-derived markers, and those based on metabolomics, are less invasive, offer reproducibility over time, and provide a comprehensive assessment of tumor biology and patient immune status, as well as allow dynamic monitoring during treatment. This review aims to evaluate the current evidence on the different candidate circulating biomarkers being investigated for their potential to predict ICI efficacy in RCC patients.

Keywords

Renal cell carcinoma, circulating biomarkers, immune-checkpoint inhibitors, liquid biopsy



Introduction

Renal cell carcinoma (RCC) accounts for around 2% of all adult malignancies [1]. It comprises different histological subtypes with different molecular characteristics, biological behavior, and response to systemic therapies [2]. Clear cell RCC (ccRCC) is the most frequent histologic subtype representing around 70–80% of all RCC [3]. At diagnosis almost 30% of cases are metastatic and around 30% will recur after surgery, and will probably require systemic therapy [4, 5].

The treatment landscape of advanced ccRCC has significantly changed during the last decade with the incorporation of immune checkpoint inhibitors (ICI) to the treatment armamentarium of advanced ccRCC. Combinations of ICI with either another ICI or an anti-angiogenic (AA), have significantly improved survival outcomes, becoming the new standard of care in first-line setting [6–14].

Despite this, there is still a notable proportion of patients that will be refractory to ICI while another subset will eventually develop resistance to ICI. Additionally, ICI are associated with non-negligible toxicities. In this context, research efforts are directed towards identifying reliable biomarkers that can help determine the best treatment strategy for our patients (i.e., ICI-ICI, ICI-AA, or even ICI or AA monotherapy).

To date, tissue-based approaches have failed to identify reliable biomarkers that are predictive of response to ICI [15]. Immunohistochemical biomarkers, such as PD-L1 or tumor infiltrating cytotoxic T cells, have been extensively studied but have failed to demonstrate a predictive role in ccRCC. Gene expression signatures developed within ICI-AA combination trials have not been validated when assessed in patients treated with dual ICI in the Checkmate 214 trial [16–18].

Circulating biomarkers emerge as an attractive alternative to tissue-based biomarkers. Blood-based biomarkers allow repeated evaluations at different time points, are easily accessible and less invasive for patients, and may be able to overcome the heterogeneity associated with biopsies. In addition, they may provide more information about the host's immune status and could be useful in determining a patient's potential for developing effective tumor immunity.

This review provides an overview of the different blood-based candidate biomarkers currently under study for predicting response to ICI in advanced RCC (aRCC).

Circulating immune cells

The effectiveness of ICI therapy is intricately linked to the host's capacity to initiate an anti-tumor immune response. Consequently, the immune profile of the host theoretically impacts the efficacy of ICI. Effector immune cells, including cytotoxic T cells and natural killer (NK) cells, are essential for the effectiveness of ICIs, as they directly attack tumor cells when checkpoint pathways are inhibited. Additionally, immune cells express checkpoint molecules such as PD-1 and CTLA-4, and the levels and activation status of these molecules can impact their function and response to ICIs [19, 20]. Regulatory T cells (Tregs) can suppress immune responses and limit the effectiveness of ICIs by inhibiting effector T cells, with high levels of Tregs in tumors counteracting checkpoint blockade effects [21]. Antigen-presenting cells (APCs) like dendritic cells and macrophages are crucial for presenting antigens to T cells and initiating immune responses, thus influencing T cell activation and the overall immune response to ICIs [22, 23]. Furthermore, cytokines produced by immune cells can modulate the immune response; for instance, interferon gamma (IFN- γ) from activated T cells can enhance PD-L1 expression in tumor cells, affecting the efficacy of ICI [24]. Tumor-associated macrophages (TAMs) can exhibit pro-inflammatory (M1-like) or anti-inflammatory (M2-like) phenotypes, with the balance between these phenotypes affecting the tumor microenvironment (TME) and the response to ICIs [25]. Additionally, interactions between immune cells and endothelial or stromal cells in the TME can influence tumor vascularization and the immune milieu, further affecting ICI efficacy [26].

Different research groups have investigated how peripheral immune cell populations influence the response to ICI therapy across different solid tumors, including ccRCC. Infiltrating cytotoxic T cells, as primary protagonists and targets of ICI therapy, have been extensively studied; however, the results in aRCC patients remains controversial [16]. Increasing evidence highlights the role of other immune cells in

the antitumor response, such as B lymphocytes [27]. Following the encouraging results of different studies supporting the role of B cells within tertiary lymphoid structures (TLS) in fostering antitumor responses across different solid tumors treated with ICI, fresh blood immune-monitoring of advanced ccRCC patients receiving nivolumab within the NIVOREN study revealed that pre-existing high levels of unswitched memory B cells (CD19⁺CD27⁺IgD⁺IgM⁺) were associated with improved clinical outcomes ($n = 44$) [overall survival (OS) HR = 0.08, $P = 0.002$ and progression-free survival (PFS) HR = 0.54, $P = 0.048$] [28] (Table 1). This B cell subset has the ability to reinitiate B cells response but also initiate a germ center reaction upon repeated antigenic stimulation [29, 30]. Interestingly, unswitched memory B cells also correlated with circulating T follicular helper (Tfh) cells, which are known to enhance B cell maturation, stimulate the expansion of T CD8⁺ lymphocytes, and with the presence of TLS. These results contrast with those reported by a pan-tumor study ($n = 78$), which included RCC patients, showing that high pretreatment levels of circulating B cells were negatively associated with response to ICI ($P < 0.001$) [31] (Table 1). The results of this study also suggest that an increased B cells frequency could identify patients at risk of progression after an initial response to ICI [31]. Finally, a small pan-tumor study, including 7 RCC tumors among the 45 different solid tumors analyzed, found that patients with increased frequency of naive B cells were more likely to benefit from ICI [disease control rate (DCR) odds ratio (OR) = 12.31, $P = 0.039$], while those with increased frequency of switched memory B cells were associated with resistance to ICI (DCR OR = 0.06, $P = 0.025$) [32] (Figure 1).

Table 1. Circulating immune cells and association with outcomes to immunotherapy in RCC

Candidate biomarker	References	Year	Country	N	Tumor	Type of systemic therapy	Parameter level/trend	Detection technique	Timepoint	Findings
Unswitched memory B cells	Carril-Ajuria et al. [28]	2022	France	44	ccRCC	Nivolumab	High	Flow cytometry	Pretreatment	Improved ORR, PFS and OS
B cells	Yuan et al. [31]	2020	China	78, 12 RCC	Pan-tumor Renal carcinoma ($n = 12$, 15.19%)	ICI	High	Flow cytometry	Pretreatment	Decreased OPR Increased PD
Naive B cells	Barth et al. [32]	2022	Austria	45, 7 RCC	Pan-tumor	ICI	Increase	Flow cytometry	Pretreatment	No significant association, neither with DCR or ORR
Switched memory B cells							Increase		On-treatment changes	Improved DCR Reduced DCR
CD8, CD4 ⁺ PD-L1 ⁺ T cells	Saliby et al. [33]	2023	US	60	Variant RCC	Atezolizumab plus bevacizumab	Large decrease	Flow cytometry	On-treatment changes	Worse PFS and OS

ccRCC: clear cell renal cell carcinoma; DCR: disease control rate; ICI: immune checkpoint inhibitors; ORR: objective response rate; OS: overall survival; PD: progressive disease; PFS: progression-free survival; RCC: renal cell carcinoma; SD: stable disease; US: United States

To understand the importance of circulating PD-L1⁺ T cells, a study investigated their relative changes at the third cycle of treatment (atezolizumab plus bevacizumab) compared to baseline levels prior to therapy [33] (Table 1). During treatment, all patients experienced a decrease in the percentage of CD8⁺PD-L1⁺ T cells. Patients with therapeutic resistance experienced a greater decrease in the percentage of CD8⁺PD-L1⁺ T cells compared to those who responded to therapy. This greater decrease in CD8⁺PD-L1⁺ T cells seemed to correlate with resistance. However, a similar trend was not clearly observed with the relative change in CD4⁺PD-L1⁺ T cells on-treatment. A larger decrease of PD-L1⁺ T cells on-treatment was associated with worse PFS and OS for both CD4⁺PD-L1⁺ T cells and CD8⁺PD-L1⁺ T cells.




Figure 1. Circulating biomarkers & outcomes to immunotherapy in RCC. BAFF: B-cell activating factor; KIM-1: Kidney-Injury Molecule-1; NLR: neutrophil-to-lymphocyte ratio; LIPI: lung immune prognostic index; PLR: platelet-to-lymphocyte ratio; SII: systemic immune inflammation; NER: neutrophil-to-eosinophil ratio; EV: extracellular vesicle; ctDNA: circulating tumor deoxyribonucleic; CTCs: circulating tumor cells; Kyn: kynurenine; Trp: tryptophan; sCD27: soluble CD27

Another small study, including 45 patients with RCC, evaluated whether the baseline diversity of the T-cell receptor β -chain (TCRB) was associated with prognosis and how the baseline and dynamic RCC tumor burdens affected the T-cell repertoire [34]. Higher TCRB diversity was shown to be connected with an increased lymphocyte-to-neutrophil ratio, especially indicating elevated naïve T cells. In addition, high baseline TCRB diversity in stage IV patients was associated with improved OS (HR = 0.195, $P = 0.037$).

In summary, although evidence on the value of circulating immune cell populations is limited, recent findings from small cohort studies provide promising results that warrant further investigation in larger prospective studies.

Inflammatory routine blood markers and derived scores

Blood-based inflammatory markers could, in theory, indicate the host's proinflammatory status and systemic immune response to cancer-related inflammation. Systemic inflammation in aRCC is associated with a poor prognosis [35, 36]. Different inflammatory routine blood parameters have been associated with worse prognosis and resistance to ICI in a variety of solid tumors, including RCC. Some of these parameters

(neutrophil count, platelets, or LDH) are well-known prognostic factors in RCC and are included in established prognostic scores used in daily clinical practice, such as the IMDC (International mRCC Database Consortium) or MSKCC (Memorial Sloan Kettering Cancer Center) scores [35, 36].

The neutrophil-to-lymphocyte ratio (NLR) is one of the most studied inflammatory markers in cancer. Reflecting the balance between systemic inflammation and adaptive immune response, it has been associated with poor prognosis across different solid tumors, including RCC. This marker has been extensively studied in aRCC, with a median NLR cut-off varying between 2.5 and 5 [37, 38] (Table 2). The most robust data on the prognostic role of NLR in RCC come from a systematic review and meta-analysis by Shao et al. [38] including 6,461 RCC patients. High NLR was associated with a poor prognosis in both localized and aRCC. In addition, elevated baseline NLR in ICI-treated aRCC patients was also associated with worse OS [38]. Recent data from the JAVELIN Renal 101 trial showed a significant association between high baseline levels of NLR (cut-off: median NLR = 2.8) and inferior clinical outcomes in both the avelumab plus axitinib (low vs. high NLR OS HR, 0.51; 95% CI, 0.300–0.871) and the sunitinib arms (low vs. high NLR OS HR, 0.30; 95% CI, 0.174–0.511), continuing to support the prognostic role of NLR in patients with aRCC [39]. Moreover, Rebuzzi et al. [40, 41] developed an improved version of the IMDC score, the “MeetURO score” by including the NLR index and the presence of bone metastases, which enabled them to split RCC patients treated with ICI into five prognostic groups. Additionally, on-therapy NLR variation has also been associated with clinical outcomes to ICI. In a retrospective study including advanced non-small cell lung cancer (NSCLC) ($n = 75$) and RCC ($n = 86$) patients, any NLR increase at week 6 was associated with worse outcomes, compared to NLR decrease [42]. Similarly, Young et al. [43] found that $\text{NLR} \geq 3$ after 12 weeks of ICI-based first-line therapy was associated with worse outcomes (17.5 months vs. 40.3 months, $P < 0.001$), and normalization of NLR in patients with baseline elevation was associated with superior OS (40.3 months vs. 14.7 months, $P = 0.004$) [43]. Monitoring NLR over time could help guide treatment intensification or de-escalation strategies; however, validation of these findings in prospective studies is still needed.

The lung immune prognostic index (LIPI), defined by pretreatment levels of derived NLR (dNLR) and LDH, was initially developed and assessed in lung cancer patients treated with ICI [44–46]. Subsequent studies have confirmed its association with clinical outcomes to ICI across other tumor types [44–50]. Until recently, the only evidence of the role of LIPI in aRCC relied on a multi-tumor retrospective study including NSCLC, melanoma and RCC (145, 25%) patients treated with ICI [47] (Table 2). In this study, LIPI stratification was associated with OS in aRCC patients treated with ICI ($P < 0.005$) [47]. The most robust data to date on the value of LIPI in aRCC come from a recent study evaluating its impact in three different prospective studies [NIVOREN study: nivolumab cohort; TORAVA trial: vascular-endothelial growth factor (VEGF)/VEGFR targeted therapy; and Checkmate 214 trial: nivolumab plus ipilimumab (nivo-ipi) vs. sunitinib] [48]. Initial results showed an association of LIPI stratification with worse outcomes in aRCC treated with nivolumab (LIPI-good 30.1 vs. 13.8 months in the LIPI intermediate/poor; HR, 0.47), but no associations with clinical outcomes were found in those treated with VEGF/VEGFR therapy, suggesting a potential predictive role for LIPI. However, this was not confirmed in the Checkmate 214 trial, where LIPI stratification was associated with worse survival outcomes irrespective of therapy type, whether nivolumab plus ipilimumab or sunitinib (nivo-ipi: LIPI good vs. intermediate/poor: HR, 0.55; $P < 0.001$; sunitinib: LIPI good vs. int/poor: HR, 0.38; $P < 0.001$) [51] (Figure 1). Thus, in contrast to NSCLC, LIPI appears to have more of a prognostic rather than a predictive value for response in aRCC.

Although their role in the immune antitumor response is less known, pre-clinical studies suggest tumor-associated eosinophilia may enhance antitumor response by promoting CD8⁺ T cell infiltration [52]. In the study by Simon et al. [53], higher levels of circulating eosinophils were associated with improved response to ICI, and eosinophils from ICI-treated patients were enriched for IFN- γ response signatures, which are known to be associated with benefit from ICI therapy. Based on these data, Zahoor et al. [54] conducted a retrospective study ($n = 90$) of aRCC patients treated with nivolumab. They found that patients with higher baseline eosinophil counts were associated with a lower risk of progression (HR, 0.54; $P = 0.042$). In contrast, the retrospective study ($n = 65$) conducted by Herrman et al. [55] failed to show a significant association between baseline circulating eosinophil counts and outcomes to ICI but found that

Table 2. Inflammatory routine laboratory derived scores and association with outcomes to immunotherapy in RCC

Candidate biomarker	References	Year	Country	N	Tumor	Timepoint	Type of systemic therapy	Cut-off/Trend indicator	Findings
NLR	Bilen et al. [39]	2022	US	886	RCC	Pretreatment	Avelumab plus axitinib or sunitinib	High	Worse OS and PFS
NLR	Simonaggio et al. [42]	2020	France	161	RCC and NSCLC	On-treatment changes	Nivolumab	Increase	Worse OS and PFS
NLR	Young et al. [43]	2024	UK	132	RCC	Pretreatment On-treatment changes	ICI combinations	≥ 3 at baseline ≥ 3 at 12 weeks Normalization of pre-treatment elevation	NS trend for worse OS Worse OS Superior OS and ORR
NLR	Ishihara et al. [136]	2019	Japan	58	RCC	Pretreatment	Nivolumab	≥ 3	Worse OS after MVA, worse PFS only on UVA
NLR	Suzuki et al. [137]	2020	Japan	65	RCC	Pretreatment	Nivolumab	≥ 5	Worse OS
NLR	Shirotake et al. [138]	2019	Japan	54	RCC	Pretreatment	Nivolumab	≥ Median value (2.89)	NS
NLR	Zahoor et al. [54]	2018	US	90	RCC	Pretreatment	Nivolumab	≥ 4.2	Worse PFS
NLR	Tucker et al. [56]	2021	US	110	RCC	Pretreatment	Nivolumab plus ipilimumab	≥ 3.42	Worse OS
LIPI	Meyers et al. [47]	2019	Canada	643	NSCLC, melanoma and RCC (145, 25%)	Pretreatment	ICI	Good LIPI, 0 factor Intermediate LIPI, 1 factor Poor LIPI, 2 factors	No difference in OS, PFS or ORR between the good and intermediate LIPI groups Worse OS and PFS
LIPI	Carril-Ajuria et al. [48]	2024	France	1,084	ccRCC	Pretreatment	Nivolumab plus ipilimumab vs. sunitinib	Intermediate/Poor LIPI (1–2 factors) vs. good LIPI (0 factor)	Worse OS in both treatment arms
NER	Zhuang et al. [139]	2023	US	184	RCC	Pretreatment	ICI	High NER > 49.2	Worse OS No significant difference for PFS
NER	Tucker et al. [56]	2021	US	110	RCC	Pretreatment	Nivolumab plus ipilimumab	≥ Median value 26.4	Worse PFS, OS and ORR
PLR	Iinuma et al. [59]	2021	Japan	43	RCC	Pretreatment	Nivolumab plus ipilimumab	High Median 215.6	Poor PFS
SII	Iinuma et al. [59]	2021	Japan	43	RCC	Pretreatment	Nivolumab plus ipilimumab	Median SII of 730	Improved survival in the SII low

ccRCC: clear cell renal cell carcinoma; ICI: immune checkpoint inhibitors; LIPI: lung immune prognostic index; MVA: multivariate; UVA: univariate; NER: neutrophil-to-eosinophil ratio; NLR: neutrophil-to-lymphocyte ratio; NS: non-significant; NSCLC: non-small cell lung cancer; ORR: objective response rate; OS: overall survival; PFS: progression-free survival; PLR: platelet-to-lymphocyte ratio; RCC: renal cell carcinoma; SII: systemic immune inflammation; UC: urothelial carcinoma; UK: United Kingdom; US: United States. Meta-analysis not included

patients experiencing an increase in eosinophils at six weeks of treatment were associated with an improved response to ICI. In the same line, Tucker et al. [56] showed that aRCC patients receiving nivolumab plus ipilimumab with lower baseline levels of neutrophil-to-eosinophil ratio (NER) presented

improved clinical outcomes compared to those with higher NER at baseline (OS HR 0.31, $P < 0.01$) [56]. In addition, the same team evaluated NER on-treatment changes and found that patients with a decreased NER at week 6 of treatment were associated with improved clinical outcomes in double ICI-treated aRCC patients (HR: 0.67, P -value: 0.002) [57] (Figure 1).

Other scores, such as the platelet-to-lymphocyte ratio (PLR) and the systemic immune-inflammation (SII) index, have also been evaluated in the context of aRCC treated with ICI. High PLR has been correlated with worse outcomes to ICI across different cancer types [58]. Similarly, Iinuma et al. [59] reported an association between high PLR and worse outcomes in aRCC patients receiving nivolumab plus ipilimumab (1-year PFS, 75.5% for low PLR vs. 49.7% for high PLR; $P = 0.034$). In this study, the SII was also associated with worse PFS, which is in line with previous studies across different cancer types ($P = 0.023$) [60].

Circulating soluble factors

Soluble factors, including cytokines and chemokines, play a critical role in anti-tumor immunity [61]. Cytokines and chemokines are released by both adaptive and innate immune cells, stromal cells, and tumor cells, and can be measured at both tissue and systemic levels. Certain soluble factors, such as IL-6, IL-8, and VEGF, are involved in carcinogenesis, myeloid inflammation, and promote immunosuppression, while others, such as the chemokine CXCL13 and the B-cell activating factor (BAFF), are involved in B cell activation, survival, and differentiation [62–64].

a) IL-6 and IL-8

Both IL-6 and IL-8 contribute to the recruitment of myeloid-derived suppressor cells to the TME, hindering the anti-tumor activity of cytotoxic T cells, and have been associated with poor clinical outcomes across different tumor types [65–69]. Tran et al. [70] observed a negative association between baseline levels of circulating IL-8 and PFS in aRCC patients treated with AAs ($P = 0.006$).

In a large multi-tumor study conducted by Schalper and colleagues [67], higher pre-treatment levels of circulating IL-8 were associated with poor outcomes in lung cancer, melanoma, and aRCC patients receiving nivolumab, double ICI, everolimus, or docetaxel, which suggests a more prognostic than predictive role (for aRCC, nivolumab OS HR: 2.56, $P < 0.001$; everolimus OS HR: 2.40, $P < 0.001$). In a post-hoc analysis of the IMmotion150 trial, higher levels of IL-8 in plasma and peripheral blood mononuclear cells (PMBCs) were linked to a poor therapeutic response to atezolizumab and lower antigen presentation in metastatic urothelial carcinoma (UC) and metastatic RCC (mRCC) patients (plasma IL-8, HR: 2.55, $P = 0.017$), even in T cell-infiltrated tumors [67, 71] (Table 3). Recent data from the NIVOREN phase 2 study not only confirm the association between elevated baseline levels of IL-8 and poor outcomes in pretreated aRCC patients treated with nivolumab (HR = 2.57, $P < 0.001$), but also show an association between baseline levels of IL-8 and the tissue-based myeloid gene expression signature of the IMmotion150 ($P = 0.041$) [72, 73]. These results are consistent with the findings of Schalper et al. [67], indicating a positive association between circulating IL-8, tumor *CXCL8* gene expression, and tumor infiltration by neutrophils, suggesting a potential involvement of these cytokines in protumoral inflammation.

Elevated circulating IL-6 is associated with a poor prognosis in localized and aRCC, however, few studies have analyzed the association between IL-6 levels and clinical outcomes in aRCC treated with ICI [74]. A small Korean study ($n = 58$) found that in aRCC patients treated with pembrolizumab plus axitinib, those with high baseline levels of circulating IL-6 exhibited significantly inferior response rates, PFS (HR: 3.51, $P = 0.003$), and OS (HR: 7.18, $P = 0.001$) compared to those with low levels of IL-6 [75] (Table 3). Moreover, CD8⁺ T cells from patients with high baseline levels of IL-6 produced less IFN- γ and TNF- α , suggesting a less effective antitumoral immune response [75]. Carril-Ajuria and colleagues [72, 73] also observed a negative association between baseline levels of IL-6 and clinical outcomes (PFS and OS) in aRCC patients treated with nivolumab within the NIVOREN study (OS HR = 3.28, $P < 0.001$). Recently, Saliby et al. [33] characterized blood- and tissue-based biomarkers in patients with variant RCC histology or any RCC

Table 3. Soluble factors and association with outcomes to immunotherapy in RCC

Candidate biomarker	References	Year	Country	N	Tumor	Detection technique	Timepoint	Type of systemic therapy	Parameter level/trend indicator	Findings
IL-8	Schalper et al. [67]	2020	US	1,344	NSCLC, melanoma and RCC	MAP immunoassay	Pretreatment	Nivolumab	High	Worse OS
IL-8	Yuen et al. [71]	2020	US	1,445	RCC and UC	Simple Plex Ella	Pretreatment	UC: chemotherapy or atezolizumab RCC : atezolizumab plus bevacizumab, atezolizumab or sunitinib	High	Worse OS in atezolizumab NS trend for worse OS in atezolizumab + bevacizumab Lower ORR but NS
IL-8	Carril-Ajuria et al. [28]	2022	France	233	RCC	MSD assay	Pretreatment	Nivolumab	High	Worse OS and PFS
IL-6	Sang et al. [75]	2022	Korea	58	RCC	Cytometric bead array assay	Pretreatment	Pembrolizumab plus axitinib	High	Worse OS and PFS
IL-6	Carril-Ajuria et al. [28]	2022	France	233	RCC	MSD assay	Pretreatment	Nivolumab	High	Worse OS and PFS
IL-1, IL-6, IL-13, MIP-1 β , and MCP-1	Saliby et al. [33]	2023	US	60	Variant RCC	Luminex fluorescent bead array platform	Pretreatment	Atezolizumab plus bevacizumab	High	Worse OS and PFS
VEGF-A and sVEGFR2	Mauge et al. [140]	2021	France	200	ccRCC	NA	Pretreatment	Nivolumab	High	Worse PFS
VEGF	Carril-Ajuria et al. [28]	2022	France	233	ccRCC	MSD assay	Pretreatment	Nivolumab	High	Worse OS
VEGF-A	Saliby et al. [33]	2023	US	60	Variant RCC	Luminex fluorescent bead array platform	Pretreatment	Atezolizumab plus bevacizumab	High	Worse OS and PFS
VEGF	Choueiri et al. [78]	2021	US	886	ccRCC	NA	Pretreatment	Avelumab plus axitinib	High	No association
CXCL13	Carril-Ajuria et al. [28]	2022	France	44	ccRCC	MSD assay	Pretreatment	Nivolumab	High	Worse OS
BAFF	Carril-Ajuria et al. [28]	2022	France	44	ccRCC	MSD assay	Pretreatment	Nivolumab	High	Worse OS
sPD-L1	Mahoney et al. [82]	2022	US	91	ccRCC	ELISA	Pretreatment	Nivolumab	High	Worse OS
sPD-L1	Incorvaia et al. [85]	2020	Italy	56	ccRCC	ELISA	Pretreatment	Nivolumab	High	Improved PFS
sCD27	Benhamouda et al. [89]	2022	France	81	ccRCC	ELISA	Pretreatment	Nivolumab	High	Worse OS

Table 3. Soluble factors and association with outcomes to immunotherapy in RCC (*continued*)

Candidate biomarker	References	Year	Country	N	Tumor	Detection technique	Timepoint	Type of systemic therapy	Parameter level/trend indicator	Findings
KIM-1	Albiges et al. [91]	2024	France	778	RCC	Affinity-based proximity extension assay (PEA) High sensitivity electrochemiluminescence (ECL)	Pretreatment	Atezolizumab	High	Reduced DFS Better DFS with atezolizumab vs. placebo

ccRCC: clear cell renal cell carcinoma; DFS: disease-free survival; MAP: human multianalyte profile immunoassay platform; MSD: Meso Scale Discovery assay; NA: not available; NS: non-significant; NSCLC: non-small cell lung cancer; ORR: objective response rate; OS: overall survival; PFS: progression-free survival; RCC: renal cell carcinoma; sCD27: soluble CD27; sPD-L1: soluble PD-L1; SS: statically significant; UC: urothelial carcinoma; US: United States; KIM-1: Kidney-Injury Molecule-1; BAFF: B-cell activating factor; VEGF: vascular-endothelial growth factor

histology with sarcomatoid differentiation, and evaluated their association with the response to atezolizumab plus bevacizumab. Interestingly, baseline levels of circulating inflammatory cytokines (IL-1, IL-6, IL-13, MIP-1 β , and MCP-1) correlated with one another, were enriched in poor IMDC patients, and were associated with worse PFS and OS under atezolizumab plus bevacizumab [33].

b) VEGF

Baseline levels of soluble VEGF-A and sVEGFR2 were associated with poor survival outcomes in treatment-naïve and pretreated advanced ccRCC patients receiving nivolumab in the BIONIKK and NIVOREN trials, respectively [72, 76] (Table 3). A small cohort study found no association between baseline levels of VEGF-A and sVEGFR2 and clinical outcomes in advanced ccRCC patients treated with pembrolizumab plus axitinib [77]. These findings could suggest that combining an AA with ICI might counteract the detrimental effect of high VEGF seen in ccRCC patients undergoing ICI monotherapy. However, results from different studies are conflicting, and the potential predictive role of soluble VEGF is still unclear. Thus, while Saliby et al. [33] reported a significant association between higher baseline levels of VEGF-A and worse PFS and OS in patients with advanced variant histology RCC treated with atezolizumab plus bevacizumab, this was not observed in aRCC patients receiving avelumab plus axitinib [78]. In addition, previous studies have also found a negative association between baseline levels of soluble VEGF and survival outcomes in advanced ccRCC patients treated with AAs [79, 80]. Overall, these findings would therefore suggest a more prognostic role. In the study by Saliby et al. [33], the impact of the on-treatment dynamic evolution of circulating VEGF-A on clinical outcomes was also evaluated. A higher increase in plasma VEGF-A throughout therapy, compared to baseline, was surprisingly associated with better clinical outcomes [33].

c) B-cell related soluble factors

Following encouraging findings from different studies suggesting B cell tumor infiltration as a predictor of response to ICI across different solid tumors, including RCC, circulating B cells populations and B-cell-related soluble factors such as CXCL13 or BAFF have also been evaluated in the context of RCC and ICI. As previously mentioned in the NIVOREN study, high levels of baseline circulating unswitched memory B cells were associated with improved response, PFS, and OS in aRCC patients treated with nivolumab [28]. Interestingly, this population of B cells was negatively correlated with baseline levels of specific B-cell-related soluble

factors: CXCL13 ($r = -0.55$, $P < 0.001$), a chemokine involved in the homeostatic organization of B-cell zones in secondary lymphoid tissue, and BAFF ($r = -0.42$, $p = 0.007$), a key factor in B-cell activation [28] (Table 3). Consistently, these two soluble factors were associated with worse survival outcomes in aRCC patients treated with nivolumab ($n = 40$). These findings were validated in an independent dataset from the same study ($n = 313$; BAFF HR: 1.73, $P = 0.002$; CXCL13 HR: 1.52, $P = 0.017$) (Figure 1).

d) Soluble PD-L1

Tumor PD-L1 is an established poor prognostic factor in aRCC; however, its role as a predictor of response to ICI is still unclear [81]. Given that PD-L1 expression can vary dynamically among both tumor and immune cells in the TME, soluble PD-L1 (sPD-L1) might offer a more accessible and representative surrogate of overall tumor

expression [75]. Building on a previous meta-analysis ($n = 1,040$) of sPD-L1 in different solid tumors, including RCC, which showed a negative association between sPD-L1 and survival outcomes, Mahoney et al. [82] analyzed serum levels of sPD-L1 in two cohorts of RCC (Checkmate 009, $n = 91$) and melanoma (Checkmate 038-Part 1, $n = 78$) patients treated with nivolumab. In the RCC cohort high baseline levels of sPD-L1 and an on-treatment increase of sPD-L1 were associated with disease progression under nivolumab (Table 3). The association of high baseline sPD-L1 with worse outcomes was confirmed in a meta-analysis ($n = 1,076$) of different solid tumor types, including RCC patients treated with ICIs [83]. It is important to note that this negative association between high baseline levels of sPD-L1 and survival has also been observed in treatment-naïve advanced ccRCC patients treated with sunitinib, which supports a more prognostic role [84]. Nevertheless, the results of another small study by Incorvaia et al. [85] show an increased PFS in RCC patients treated with ICI with high baseline sPD-L1 levels compared to those with low baseline sPD-L1. Thus, the role of sPD-L1 in aRCC treated with ICI still remains controversial.

e) Soluble CD27

CD70 is a costimulatory molecule known to stimulate CD27-expressing T cells, such as naïve and central memory T cells. The interaction between CD27 and CD70 results in the release of soluble CD27 (sCD27). However, prolonged exposure to CD27-CD70 costimulatory signals can exhaust the T-cell pool and lead to depletion of naïve T cells [86–88]. Interestingly, ccRCC expresses the highest levels of CD70 among solid tumors. In a recent study by Benhamouda and colleagues [89], TME CD27⁺ T cells from ccRCC patients were associated with an apoptotic and dysfunctional signature compared to CD27⁻ T cells. In addition, intratumoral CD27-CD70 interaction correlated with sCD27. Consistently, higher baseline levels of sCD27 were associated with poor OS in ICI-treated patients (HR: 5.02, $P = 0.004$) but not in patients treated with AA therapy ($P = 0.35$), suggesting that sCD27 could serve not only as a surrogate marker of T cell dysfunction in the TME but also as a potential ICI-resistance biomarker [89] (Table 3). However, validation in larger prospective randomized clinical trials is needed before incorporation into routine clinical practice.

f) Circulating proteins

The Kidney-Injury Molecule-1 (KIM-1), a transmembrane protein highly expressed in RCC and whose ectodomain circulates and can be detected in plasma, has also gained interest in the last years [90].

A post-hoc analysis from the ASSURE trial, which evaluated the benefit of adjuvant sunitinib or sorafenib vs. placebo in high-risk resected RCC patients, found a significant association between high levels of circulating KIM-1 post-nephrectomy and worse disease-free survival (DFS) (HR: 0.56, $P < 0.001$) and OS (HR: 0.71, $P < 0.001$) [90]. Recently, the results from an exploratory analysis of the IMmotion010 trial not only confirmed the association between high baseline levels of circulating KIM-1 and worse prognosis in high-risk resected RCC patients, but also found an association between post-nephrectomy levels of circulating KIM-1 and improved clinical outcomes with atezolizumab vs. placebo (HR: 0.72, 95% CI: 0.53–0.99) (Table 3). These results, therefore, suggest that circulating KIM-1 could be a marker of minimal residual disease (MRD) and may also behave as both a biomarker of poor prognosis and a predictive biomarker of atezolizumab efficacy in the adjuvant setting [91].

A recent cohort study including 36 ccRCC patients conducted by Lucarelli and colleagues [92] reported that tumor expressing high levels vs. those expressing low levels of the transmembrane glycoprotein mucin 1 (MUC1) were associated with an altered metabolism, higher vascularization, lower immune infiltration and higher M2-tumor associated macrophage response, and lower PD-L1 expression, suggesting these tumors would theoretically derive less benefit from ICI. They also found that the soluble form of MUC1, the cancer antigen (CA) 15.3, was associated with higher nuclear grade, lymph node involvement and visceral metastases ($P < 0.001$), as well as with inferior cancer specific survival and PFS ($P = 0.01$) [92]. Although hypothesis-raising, both MUC1 and circulating CA 15.3 still need to be evaluated in the context of ICI treatment.

Circulating tumor-derived biomarkers

The idea of measuring tumor-derived blood biomarkers is not new. For years, and in several cancer types, we have used different tumor protein markers such as CA 15.3, CA 125, prostate-specific antigen (PSA), or carcinoembryonic antigen (CEA) to detect disease recurrence, progression, and response to therapy [93]. However, these tumor markers lack specificity and are not able to predict response to specific treatment types and thus guide treatment selection. During the last decade, new tumor-derived biomarkers such as circulating tumor cells (CTCs), circulating tumor deoxyribonucleic (DNA; ctDNA) and micro-ribonucleic acids (miRNAs) have been developed. This is what we commonly refer to as liquid biopsy, and it has the potential to help us detect cancer, guide treatment selection, assess real-time tumor response to therapy, and identify resistant clones [94].

a) Circulating tumor cells

CTCs are cancer cells that circulate in the bloodstream after being shed from primary or metastatic tumors. CTCs have been shown to be associated with prognosis across different solid tumors [95–99]. Currently, there is no standardized CTC detection method [100, 101]. Given that CTCs have been implicated in tumor metastasis and recurrence, they are difficult to detect in early-stage RCC. In a recent meta-analysis including 12 studies and 767 RCC patients, CTCs were more likely to be found in advanced than in localized disease (OR, 2.29; $P = 0.002$). Curiously, the sensitivity of CTCs in ccRCC (69%) was significantly higher than in non-ccRCC subtypes (34%) [100]. CTCs are associated with poor prognosis in both localized and aRCC [102–104]. Basso et al. [105] reported worse survival outcomes for aRCC patients receiving first-line AA therapy with ≥ 3 CTCs at baseline, although an association with response was not observed ($n = 95$). Only one study has evaluated the role of CTCs in the context of ICI. In this study, Bootsma et al. [106] profiled 457 blood samples collected longitudinally from 104 aRCC patients receiving ICI, confirming that CTC enumeration is prognostic in aRCC treated with ICI (Table 4). Moreover, an on-treatment increase in CTC levels was strongly and negatively associated with OS [106] (Figure 1). They also investigated the expression of HLA I to PD-L1 (HP ratio) by CTCs. Interestingly, the HP ratio decreased over time in patients treated with ICI, raising the hypothesis that tumor cells with high HLA I and low PD-L1 would be more likely to be cleared by ICI. Additionally, if a patient's HP ratio does not drop during ICI therapy, it could suggest a poor response [106].

b) Tumor nucleic acids

Extracellular tumor DNA, also known as cell-free DNA (cfDNA), and ctDNA, which represents the portion of mutated cfDNA derived from cancer cells, can also be detected in plasma samples [107]. Various studies have demonstrated the diagnostic utility of cfDNA. For instance, Feng et al. [108] observed significant differences in cfDNA levels between RCC patients and healthy controls, noting correlations with tumor stage, grade, and metastatic burden. Additionally, cfDNA methylation has also shown promising results [109–111]. Conversely, the detection of ctDNA in renal cancer is lower than in other cancers, which limits its use as a diagnostic tool [112, 113]. However, results of a recent Korean study ($n = 48$) suggest that ctDNA could predict pT3a upstaging in cT1a ccRCC tumors [114]. Moreover, results from a recent study assessing MRD in the adjuvant setting with 61 RCC patients suggest ctDNA, although not ready for primetime, could have the potential to guide adjuvant treatment [115]. In this study, ctDNA negative

Table 4. Circulating tumor-derived biomarkers and association with outcomes to immunotherapy in RCC

Candidate biomarker	References	Year	Country	N	Tumor	Timepoint	Type of systemic therapy	Parameter level/trend indicator	Detection technique	Findings
Circulating tumor cells	Bootsma et al. [106]	2022	US	104	RCC	Pre-treatment On-treatment	ICI	High Increase	Nikon Ti-E microscope with automated XYZ stage	Worse OS
Circulating tumor DNA	Maia et al. [119]	2017	Brazil	34	RCC	Pretreatment	Different types of systemic therapy, including ICI		College of American Pathology-accredited comprehensive plasma assay	No significant associations
Circulating tumor DNA	Chehrazhi-Raffle et al. [120]	2023	US	12	RCC	Pretreatment	ICI	Median VAFs	TARDIS	Distinguished those achieving PR (0.181%) from those with CR (0.007%)
EV microRNA-155-3p	Soleimani et al. [126]	2024	Canada	40	RCC	Pretreatment	-Ipilimumab plus nivolumab - Pembrolizumab plus axitinib -Avelumab plus axitinib		exoRNeasy serum/plasma midi kit Applied Biosystems TaqMan assays TaqMan microRNA RT kit + TaqMan miRNA assay	Lower levels in responders

CR: complete response; ICI: immune checkpoint inhibitors; OS: overall survival; PR: partial response; RCC: renal cell carcinoma; US: United States; EV: extracellular vesicle; miRNAs: micro-ribonucleic acids

patients in the non-adjuvant cohort had a negative predictive value of 92%. Additionally, several studies have identified cfDNA levels as prognostic markers in localized RCC [110, 116]. Yamamoto and colleagues [117] confirmed the prognostic role of cfDNA levels in both localized and mRCC patients. Regarding the role of cfDNA as a predictor of response to systemic therapy, data are still scarce with only a few small cohort studies. Feng et al. [108] observed that cfDNA decreased in RCC patients responding to sorafenib, while cfDNA levels increased in non-responders. In the study by Yamamoto et al. [117], persistence of detectable DNA was associated with an inferior response to AAs. Similarly, cfDNA levels at baseline were associated with a higher response and improved PFS/OS in RCC patients receiving either ICI or TKI [118]. Conversely, no significant associations between ctDNA levels and OS were observed in RCC patients treated with different types of systemic therapy [119]. Recently, Chehrazhi-Raffle et al. [120] tested a novel ultrasensitive DNA assay (TARDIS, targeted digital sequencing) in 12 RCC patients undergoing ICI-based therapy (either nivolumab or nivolumab plus ipilimumab) with promising results (Table 4). TARDIS was able to distinguish those achieving partial response (PR) from those achieving complete response (CR), and to prospectively identify patients with subsequent progression [120]. Finally, several studies have demonstrated a low gene alteration (GA) concordance between ctDNA and tumor tissue sequencing, which raises concerns about its potential use to guide treatment selection [118].

miRNAs are small non-coding RNAs that play a key role in regulating gene expression [121]. Although several studies have investigated the role of miRNAs in RCC detection, to date, there is only one study, with reported results evaluating the role of miRNAs as predictors of response to ICI in aRCC [122–126]. In this study, Soleimani et al. [126] investigated the presence of immune-specific extracellular vesicle (EV) miRNAs in the plasma of aRCC patients before ICI initiation. miRNA-155-3p was significantly lower in responders compared to non-responders (Table 4; Figure 1). These results suggest that miRNA-155-3p could be a predictor of response to ICI in RCC, and are consistent with those reported in melanoma patients treated with ICI [126–128]. Interestingly, in another study constructing a four-miRNA model for RCC screening,

miRNA-155-5p was able to distinguish between RCC patients and normal controls, while also displaying a significant association with prognosis [129]. Although these data warrant further validation, they are also supported by a biological rationale. miRNA-155-3p is the result of the *MIRHG155* gene, also known as the “B-cell Integration Cluster (*BIC*) gene” or “Master regulator of inflammation”, due to its role in modulating the inflammatory response and its critical implication in the diversification of the antibody repertoire [130]. This is consistent with the emerging evidence supporting the role of B cells in the antitumor immune response.

Overall, liquid biopsy is a non-invasive and repeatable tool that allows to monitor the dynamic evaluation of tumors. Although detection rates are low, recent studies have shown promising results suggesting further investigation of liquid biopsy components such as cfDNA, ctDNA, and EV miRNAs. These studies could potentially help us guide treatment selection and decisions regarding treatment de-escalation or intensification in aRCC.

Metabolomics

The tryptophan-kynurenine-aryl hydrocarbon receptor (Trp-Kyn-AhR) pathway contributes to immunosuppression in T cell inflamed tumors [131]. Kyn results from Trp catabolism by indoleamine 2,3-dioxygenase (IDO) or tryptophan 2,3-dioxygenase (TDO) [132]. Trp degradation and depletion contribute to tumor evasion, while increasing Kyn metabolites which contribute to immunosuppression and cancer progression [132]. Despite promising results in previous preclinical studies showing that suppression of this pathway could enhance ICI efficacy, the combination of a selective IDO1 inhibitor and pembrolizumab in unselected melanoma patients failed to improve outcomes in a phase 3 randomized study [133, 134]. Recently, Li and colleagues [135] conducted a comprehensive study of the Trp-Kyn pathway in melanoma and RCC patients treated with nivolumab. In this study, treatment with PD-1 blockade induced Trp/Kyn conversion. More importantly, the increase of the Kyn/Trp ratio during treatment was a predictor of survival in both cohorts of melanoma and RCC, and it was further validated in a larger independent study comparing nivolumab vs. everolimus in pretreated RCC patients. At week 4, the Kyn/Trp increase was significantly associated with worse OS in the nivolumab arm but not in the everolimus arm (Figure 1). These results suggest that serum Kyn/Trp monitoring could help identify which patients are more likely to benefit from IDO and PD-1 inhibition and deserve further study.

Conclusions

Current research on circulating biomarkers for predicting response to ICI treatment in RCC is promising, although it is still in its early stages (Figure 1). In addition, circulating biomarkers have not been extensively studied in the context of ICI combination therapy in aRCC, the standard of care in first-line setting. However, these biomarkers, encompassing immune cell populations, soluble factors, ctDNA, CTCs, and metabolomic profiles, hold significant potential. Compared to tissue biopsies, they are less invasive, potentially more comprehensive, and may enable real-time monitoring. The analysis of immune cell populations and circulating soluble factor seems to provide valuable insights into the immune landscape and real-time monitoring that could help identify patients who are resistant or responsive to ICI. Meanwhile circulating DNA and CTCs could help guide treatment selection and de-escalation/intensification strategies, by identifying patients at higher risk of recurrence and by discerning good from poor responders. Circulating biomarkers hold the potential to help us identify which patients will benefit most from double ICI therapy or ICI-AA therapy.

To harness these potentials, it is essential to standardize detection methods and establish consistent cut-offs, and validate these biomarkers in large, randomized clinical trials. Moreover, achieving meaningful predictive accuracy will likely require the integration of multiple biomarkers and multiomics techniques. Studies like the pragmatic European CARE1 trial, which evaluates double ICI against ICI-AA therapy, are incorporating integrated circulating biomarkers studies that could provide new insights. Integration of biomarker studies into clinical trials will be essential for advancing these biomarkers towards clinical practice.

Abbreviations

AA: anti-angiogenic
aRCC: advanced renal cell carcinoma
BAFF: B-cell activating factor
CA: cancer antigen
ccRCC: clear cell renal cell carcinoma
cfDNA: cell-free deoxyribonucleic
CR: complete response
CTCs: circulating tumor cells
ctDNA: circulating tumor deoxyribonucleic
DCR: disease control rate
DFS: disease-free survival
DNA: deoxyribonucleic
EV: extracellular vesicle
ICI: immune checkpoint inhibitors
IDO: indoleamine 2,3-dioxygenase
IFN- γ : interferon gamma
KIM-1: Kidney-Injury Molecule-1
Kyn: kynurenine
LIPI: lung immune prognostic index
miRNAs: micro-ribonucleic acids
mRCC: metastatic renal cell carcinoma
MUC1: mucin 1
NER: neutrophil-to-eosinophil ratio
NLR: neutrophil-to-lymphocyte ratio
NSCLC: non-small cell lung cancer
OR: odds ratio
OS: overall survival
PFS: progression-free survival
PLR: platelet-to-lymphocyte ratio
PR: partial response
RCC: renal cell carcinoma
sCD27: soluble CD27
SII: systemic immune inflammation
sPD-L1: soluble PD-L1
TCRB: T-cell receptor β -chain
TME: tumor microenvironment
Trp: tryptophan

UC: urothelial carcinoma

VEGF: vascular-endothelial growth factor

Declarations

Author contributions

LO: Conceptualization, Investigation, Writing—original draft. MN: Visualization. RF, JGD, JPF, DN, CA, AAS, NC, GdV, and LA: Writing—review & editing. LCA: Conceptualization, Investigation, Writing—original draft.

Conflicts of interest

RF: Honoraria: Bayer, Astellas, Janssen, BMS, MSD, Ipsen, Pfizer, Merck, Astra Zeneca. NC has provided expertise through participation in scientific advisory boards to AstraZeneca and to Servier and received a research grant from Cytune Pharma, Roche, and Sanofi, although these grants were not on the matter of this manuscript. GdV: grants and personal fees from Pfizer, Roche, and Ipsen; and personal fees from Bristol-Myers Squibb, Astellas, Janssen, Bayer, Merck, and MSD. LA: Consulting or Advisory Role: Astellas Pharma (Inst), Bristol-Myers Squibb (Inst), Eisai (Inst), Ipsen (Inst), Janssen (Inst), MSD (Inst), Pfizer (Inst), Roche (Inst). Travel, Accommodations, Expenses: BMS, Ipsen, MSD. LCA: Travel/accommodation: Pfizer, Ipsen, BMS. Honoraria: Ipsen, Janssen. The rest of authors declare no competing interests.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

© The Author(s) 2024.

References

1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2024;74:229–63. [DOI] [PubMed]
2. Cimadamore A, Massari F, Santoni M, Mollica V, Di Nunno V, Cheng L, et al. Molecular characterization and diagnostic criteria of renal cell carcinoma with emphasis on liquid biopsies. *Expert Rev Mol Diagn*. 2020;20:141–50. [DOI] [PubMed]
3. Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, et al. Renal cell carcinoma. *Nat Rev Dis Primers*. 2017;3:17009. [DOI] [PubMed] [PMC]
4. Choueiri TK, Motzer RJ. Systemic Therapy for Metastatic Renal-Cell Carcinoma. *N Engl J Med*. 2017; 376:354–66. [DOI] [PubMed]
5. Bianchi M, Sun M, Jeldres C, Shariat SF, Trinh QD, Briganti A, et al. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. *Ann Oncol*. 2012;23:973–80. [DOI] [PubMed]

6. Motzer RJ, Jonasch E, Agarwal N, Alva A, Baine M, Beckermann K, et al. Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2022;20:71–90. [\[DOI\]](#) [\[PubMed\]](#) [\[PMC\]](#)
7. Rizzo A, Rosellini M, Marchetti A, Mollica V, Massari F. Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: a critical overview of recent evidence. *Immunotherapy*. 2021;13:685–92. [\[DOI\]](#) [\[PubMed\]](#)
8. Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. *N Engl J Med*. 2019;380:1103–15. [\[DOI\]](#) [\[PubMed\]](#) [\[PMC\]](#)
9. Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, et al.; CLEAR Trial Investigators. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. *N Engl J Med*. 2021;384:1289–300. [\[DOI\]](#) [\[PubMed\]](#)
10. Choueiri TK, Powles T, Burotto M, Escudier B, Boursion MT, Zurawski B, et al.; CheckMate 9ER Investigators. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. *N Engl J Med*. 2021;384:829–41. [\[DOI\]](#) [\[PubMed\]](#) [\[PMC\]](#)
11. Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, et al.; CheckMate 214 Investigators. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. *N Engl J Med*. 2018;378:1277–90. [\[DOI\]](#) [\[PubMed\]](#) [\[PMC\]](#)
12. Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al.; KEYNOTE-426 Investigators. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. *N Engl J Med*. 2019;380:1116–27. [\[DOI\]](#) [\[PubMed\]](#)
13. Chen YW, Wang L, Panian J, Dhanji S, Derweesh I, Rose B, et al. Treatment Landscape of Renal Cell Carcinoma. *Curr Treat Options Oncol*. 2023;24:1889–916. [\[DOI\]](#) [\[PubMed\]](#) [\[PMC\]](#)
14. Pezzicoli G, Ganini C, Re Sartò GV, Pirovano M, Cosmai L, Porta C. The Treatment of Metastatic Renal Cell Carcinoma: An Update. *G Ital Nefrol*. 2023;40:2023–S81. Italian. [\[PubMed\]](#)
15. Hofman P, Heeke S, Alix-Panabières C, Pantel K. Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients? *Ann Oncol*. 2019;30:1448–59. [\[DOI\]](#) [\[PubMed\]](#)
16. Motzer RJ, Robbins PB, Powles T, Albiges L, Haanen JB, Larkin J, et al. Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. *Nat Med*. 2020;26:1733–41. [\[DOI\]](#) [\[PubMed\]](#) [\[PMC\]](#)
17. McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. *Nat Med*. 2018;24:749–57. [\[DOI\]](#) [\[PubMed\]](#) [\[PMC\]](#)
18. Motzer RJ, Choueiri TK, McDermott DF, Powles T, Vano YA, Gupta S, et al. Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma. *J Immunother Cancer*. 2022;10:e004316. [\[DOI\]](#) [\[PubMed\]](#) [\[PMC\]](#)
19. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. *Science*. 2018;359:1350–5. [\[DOI\]](#) [\[PubMed\]](#) [\[PMC\]](#)
20. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. *Nature*. 2011;480:480–9. [\[DOI\]](#) [\[PubMed\]](#) [\[PMC\]](#)
21. Togashi Y, Shitara K, Nishikawa H. Regulatory T cells in cancer immunosuppression - implications for anticancer therapy. *Nat Rev Clin Oncol*. 2019;16:356–71. [\[DOI\]](#) [\[PubMed\]](#)
22. Gardner A, Ruffell B. Dendritic Cells and Cancer Immunity. *Trends Immunol*. 2016;37:855–65. [\[DOI\]](#) [\[PubMed\]](#) [\[PMC\]](#)
23. Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. *Immunity*. 2014;41:49–61. [\[DOI\]](#) [\[PubMed\]](#) [\[PMC\]](#)
24. Spranger S, Spaepen RM, Zha Y, Williams J, Meng Y, Ha TT, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. *Sci Transl Med*. 2013;5:200ra116. [\[DOI\]](#) [\[PubMed\]](#) [\[PMC\]](#)

25. Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. *Nat Rev Clin Oncol*. 2017;14:399–416. [DOI] [PubMed] [PMC]
26. Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. *Science*. 2015;348:74–80. [DOI] [PubMed]
27. Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, et al. B cells and tertiary lymphoid structures promote immunotherapy response. *Nature*. 2020;577:549–55. [DOI] [PubMed] [PMC]
28. Carril-Ajuria L, Desnoyer A, Meylan M, Dalban C, Naigeon M, Cassard L, et al. Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study. *J Immunother Cancer*. 2022;10:e004885. [DOI] [PubMed] [PMC]
29. Viant C, Wirthmiller T, ElTanbouly MA, Chen ST, Kara EE, Cipolla M, et al. Germinal center-dependent and -independent memory B cells produced throughout the immune response. *J Exp Med*. 2021;218:e20202489. [DOI] [PubMed] [PMC]
30. Dogan I, Bertocci B, Vilmont V, Delbos F, Mégret J, Storck S, et al. Multiple layers of B cell memory with different effector functions. *Nat Immunol*. 2009;10:1292–9. [DOI] [PubMed]
31. Yuan S, Liu Y, Till B, Song Y, Wang Z. Pretreatment Peripheral B Cells Are Associated With Tumor Response to Anti-PD-1-Based Immunotherapy. *Front Immunol*. 2020;11:563653. [DOI] [PubMed] [PMC]
32. Barth DA, Stanzer S, Spiegelberg JA, Bauernhofer T, Absenger G, Szkandera J, et al. Patterns of Peripheral Blood B-Cell Subtypes Are Associated With Treatment Response in Patients Treated With Immune Checkpoint Inhibitors: A Prospective Longitudinal Pan-Cancer Study. *Front Immunol*. 2022;13:840207. [DOI] [PubMed] [PMC]
33. Saliby RM, El Zarif T, Bakouny Z, Shah V, Xie W, Flippot R, et al. Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma. *Cancer Immunol Res*. 2023;11:1114–24. [DOI] [PubMed] [PMC]
34. Guo L, Bi X, Li Y, Wen L, Zhang W, Jiang W, et al. Characteristics, dynamic changes, and prognostic significance of TCR repertoire profiling in patients with renal cell carcinoma. *J Pathol*. 2020;251:26–37. [DOI] [PubMed] [PMC]
35. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. *J Clin Oncol*. 1999;17:2530–40. [DOI] [PubMed]
36. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. *J Clin Oncol*. 2009;27:5794–9. [DOI] [PubMed]
37. Hu K, Lou L, Ye J, Zhang S. Prognostic role of the neutrophil-lymphocyte ratio in renal cell carcinoma: a meta-analysis. *BMJ Open*. 2015;5:e006404. [DOI] [PubMed] [PMC]
38. Shao Y, Wu B, Jia W, Zhang Z, Chen Q, Wang D. Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis. *BMC Urol*. 2020;20:90. [DOI] [PubMed] [PMC]
39. Bilen MA, Rini BI, Voss MH, Larkin J, Haanen J, Albiges L, et al. Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial. *Clin Cancer Res*. 2022;28:738–47. [DOI] [PubMed] [PMC]
40. Rebuzzi SE, Signori A, Banna GL, Maruzzo M, De Giorgi U, Pedrazzoli P, et al. Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). *Ther Adv Med Oncol*. 2021;13:17588359211019642. [DOI] [PubMed] [PMC]

41. Rebuzzi SE, Signori A, Buti S, Banna GL, Murianni V, Damassi A, et al. Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program. *ESMO Open*. 2022;7:100634. [DOI] [PubMed] [PMC]
42. Simonaggio A, Elaidi R, Fournier L, Fabre E, Ferrari V, Borchellini D, et al. Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab. *Cancer Immunol Immunother*. 2020;69:2513–22. [DOI] [PubMed] [PMC]
43. Young M, Tapia JC, Szabados B, Jovaisaite A, Jackson-Spence F, Nally E, et al. NLR Outperforms Low Hemoglobin and High Platelet Count as Predictive and Prognostic Biomarker in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. *Clin Genitourin Cancer*. 2024;22:102072. [DOI] [PubMed]
44. Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, et al. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. *JAMA Oncol*. 2018;4:351–7. [DOI] [PubMed] [PMC]
45. Sorich MJ, Rowland A, Karapetis CS, Hopkins AM. Evaluation of the Lung Immune Prognostic Index for Prediction of Survival and Response in Patients Treated With Atezolizumab for NSCLC: Pooled Analysis of Clinical Trials. *J Thorac Oncol*. 2019;14:1440–6. [DOI] [PubMed]
46. Kazandjian D, Gong Y, Keegan P, Pazdur R, Blumenthal GM. Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non-Small Cell Lung Cancer. *JAMA Oncol*. 2019;5:1481–5. [DOI] [PubMed] [PMC]
47. Meyers DE, Stukalin I, Vallerand IA, Lewinson RT, Suo A, Dean M, et al. The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors. *Cancers (Basel)*. 2019;11:1713. [DOI] [PubMed] [PMC]
48. Carril-Ajuria L, Lavaud P, Dalban C, Negrier S, Gravis G, Motzer RJ, et al. Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma. *Eur J Cancer*. 2024;204:114048. [DOI] [PubMed]
49. Parent P, Auclin E, Patrikidou A, Mezquita L, Martínez Chanzá N, Dumont C, et al. Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract Carcinoma. *Cancers (Basel)*. 2023;15:1066. [DOI] [PubMed] [PMC]
50. Auclin E, Vuagnat P, Smolenschi C, Taieb J, Adeva J, Nebot-Bral L, et al. Association of the Lung Immune Prognostic Index with Immunotherapy Outcomes in Mismatch Repair Deficient Tumors. *Cancers (Basel)*. 2021;13:3776. [DOI] [PubMed] [PMC]
51. Yamashita S, Hamamoto S, Furukawa J, Fujita K, Takahashi M, Miyake M, et al. Association of lung immune prognostic index with survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. *Jpn J Clin Oncol*. 2024;54:722–9. [DOI] [PubMed]
52. Carretero R, Sektioglu IM, Garbi N, Salgado OC, Beckhove P, Hämmerling GJ. Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. *Nat Immunol*. 2015;16:609–17. [DOI] [PubMed]
53. Simon SCS, Hu X, Panten J, Grees M, Renders S, Thomas D, et al. Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors. *Oncoimmunology*. 2020;9:1727116. [DOI] [PubMed] [PMC]
54. Zahoor H, Barata PC, Jia X, Martin A, Allman KD, Wood LS, et al. Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab. *J Immunother Cancer*. 2018;6:107. [DOI] [PubMed] [PMC]
55. Herrmann T, Ginzac A, Molnar I, Bailly S, Durando X, Mahammed H. Eosinophil counts as a relevant prognostic marker for response to nivolumab in the management of renal cell carcinoma: a retrospective study. *Cancer Med*. 2021;10:6705–13. [DOI] [PubMed] [PMC]

56. Tucker MD, Brown LC, Chen YW, Kao C, Hirshman N, Kinsey EN, et al. Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma. *Biomark Res.* 2021;9:80. [DOI] [PubMed] [PMC]
57. Chen YW, Tucker MD, Brown LC, Yasin HA, Ancell KK, Armstrong AJ, et al. The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma. *Cancers (Basel).* 2022;14:3830. [DOI] [PubMed] [PMC]
58. Xu H, He A, Liu A, Tong W, Cao D. Evaluation of the prognostic role of platelet-lymphocyte ratio in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. *Int Immunopharmacol.* 2019;77:105957. [DOI] [PubMed]
59. Iinuma K, Enomoto T, Kawada K, Fujimoto S, Ishida T, Takagi K, et al. Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab. *J Clin Med.* 2021;10:5325. [DOI] [PubMed] [PMC]
60. Wang Y, Ni Q. Prognostic and clinicopathological significance of Systemic Immune-Inflammation Index in cancer patients receiving immune checkpoint inhibitors: a meta-analysis. *Ann Med.* 2023;55:808–19. [DOI] [PubMed] [PMC]
61. Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, et al. Loss of IFN- γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. *Cell.* 2016;167:397–404.e9. [DOI] [PubMed] [PMC]
62. Horikawa N, Abiko K, Matsumura N, Hamanishi J, Baba T, Yamaguchi K, et al. Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells. *Clin Cancer Res.* 2017;23:587–99. [DOI] [PubMed]
63. Dai S, Zeng H, Liu Z, Jin K, Jiang W, Wang Z, et al. Intratumoral CXCL13⁺CD8⁺T cell infiltration determines poor clinical outcomes and immunoevasive contexture in patients with clear cell renal cell carcinoma. *J Immunother Cancer.* 2021;9:e001823. [DOI] [PubMed] [PMC]
64. Mackay F, Browning JL. BAFF: a fundamental survival factor for B cells. *Nat Rev Immunol.* 2002;2:465–75. [DOI] [PubMed]
65. Fousek K, Horn LA, Palena C. Interleukin-8: A chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression. *Pharmacol Ther.* 2021;219:107692. [DOI] [PubMed] [PMC]
66. Quan Z, He Y, Luo C, Xia Y, Zhao Y, Liu N, et al. Interleukin 6 induces cell proliferation of clear cell renal cell carcinoma by suppressing hepaCAM via the STAT3-dependent up-regulation of DNMT1 or DNMT3b. *Cell Signal.* 2017;32:48–58. [DOI] [PubMed]
67. Schalper KA, Carleton M, Zhou M, Chen T, Feng Y, Huang SP, et al. Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors. *Nat Med.* 2020;26:688–92. [DOI] [PubMed] [PMC]
68. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. *Nat Rev Immunol.* 2009;9:162–74. [DOI] [PubMed] [PMC]
69. Giraldo NA, Becht E, Vano Y, Petitprez F, Lacroix L, Validire P, et al. Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma. *Clin Cancer Res.* 2017;23:4416–28. [DOI] [PubMed]
70. Tran HT, Liu Y, Zurita AJ, Lin Y, Baker-Neblett KL, Martin AM, et al. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. *Lancet Oncol.* 2012;13:827–37. [DOI] [PubMed]
71. Yuen KC, Liu LF, Gupta V, Madireddi S, Keerthivasan S, Li C, et al. High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade. *Nat Med.* 2020;26:693–8. [DOI] [PubMed] [PMC]

72. Carril-Ajuria L, Naigeon M, Dalban C, Desnoyer A, Rioux-Leclercq N, Sautès-Fridma C n, et al. Baseline circulating soluble factors as predictors of immune-related adverse events (irAEs) in patients (pts) with metastatic clear cell renal carcinoma (mRCC) treated with nivolumab: A translational NIVOREN GETUG-AFU 26 study. *JCO*. 2023;41:724. [DOI]
73. Ajuria LC, Naigeon M, Flippot R, Dalban C, Desnoyer A, Rioux-Leclercq N, et al. 184P Elevated baseline circulating IL-8 is associated with increased expression of the IMmotion myeloid gene signature (GS) in metastatic clear cell renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (nivo) within the NIVOREN GETUG-AFU 26 study. *Immunooncol Technol*. 2023;20:100643. [DOI]
74. Wang Y, Zhang Y. Prognostic role of interleukin-6 in renal cell carcinoma: a meta-analysis. *Clin Transl Oncol*. 2020;22:835–43. [DOI] [PubMed]
75. Sang YB, Yang H, Lee WS, Lee SJ, Kim SG, Cheon J, et al. High Serum Levels of IL-6 Predict Poor Responses in Patients Treated with Pembrolizumab plus Axitinib for Advanced Renal Cell Carcinoma. *Cancers (Basel)*. 2022;14:5985. [DOI] [PubMed] [PMC]
76. Epailard N, Simonaggio A, Elaidi R, Azzouz F, Braychenko E, Thibault C, et al. BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer. *Bull Cancer*. 2020;107:eS22–7. [DOI] [PubMed]
77. Martini JF, Plimack ER, Choueiri TK, McDermott DF, Puzanov I, Fishman MN, et al. Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma. *Clin Cancer Res*. 2020;26:5598-608. [DOI] [PubMed]
78. Choueiri TK, Donahue AC, Rini BI, Powles T, Haanen JBAG, Larkin J, et al. Integrating peripheral biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). *JCO*. 2021;39:4547. [DOI]
79. Kut C, Mac Gabhann F, Popel AS. Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. *Br J Cancer*. 2007;97:978–85. [DOI] [PubMed] [PMC]
80. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. *J Clin Oncol*. 2009;27:3312–8. [DOI] [PubMed]
81. Massouh Skorin R, Escovar la Riva P, Gabler F, Kirmayr M, Khamis T, Escobar S, et al. Expression of PD-L1 in renal cancer, prognostic features and clinical utility of its routine staining. *Actas Urol Esp (Engl Ed)*. 2023;47:271–8. [DOI] [PubMed]
82. Mahoney KM, Ross-Macdonald P, Yuan L, Song L, Veras E, Wind-Rotolo M, et al. Soluble PD-L1 as an early marker of progressive disease on nivolumab. *J Immunother Cancer*. 2022;10:e003527. [DOI] [PubMed] [PMC]
83. Scirocchi F, Strigari L, Di Filippo A, Napoletano C, Pace A, Rahimi H, et al. Soluble PD-L1 as a Prognostic Factor for Immunotherapy Treatment in Solid Tumors: Systematic Review and Meta-Analysis. *Int J Mol Sci*. 2022;23:14496. [DOI] [PubMed] [PMC]
84. Montemagno C, Hagege A, Borchellini D, Thamphya B, Rastoin O, Ambrosetti D, et al. Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma. *Oncoimmunology*. 2020;9:1846901. [DOI] [PubMed] [PMC]
85. Incorvaia L, Fanale D, Badalamenti G, Porta C, Olive D, De Luca I, et al. Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions. *Oncoimmunology*. 2020;9:1832348. [DOI] [PubMed] [PMC]
86. Nolte MA, van Olfen RW, van Gisbergen KP, van Lier RA. Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology. *Immunol Rev*. 2009;229:216–31. [DOI] [PubMed]

87. Huang J, Jochems C, Anderson AM, Talaie T, Jales A, Madan RA, et al. Soluble CD27-pool in humans may contribute to T cell activation and tumor immunity. *J Immunol.* 2013;190:6250–8. [DOI] [PubMed] [PMC]
88. Tesselaar K, Arens R, van Schijndel GM, Baars PA, van der Valk MA, Borst J, et al. Lethal T cell immunodeficiency induced by chronic costimulation via CD27-CD70 interactions. *Nat Immunol.* 2003;4:49–54. [DOI] [PubMed]
89. Benhamouda N, Sam I, Epailard N, Gey A, Phan L, Pham HP, et al. Plasma CD27, a Surrogate of the Intratumoral CD27-CD70 Interaction, Correlates with Immunotherapy Resistance in Renal Cell Carcinoma. *Clin Cancer Res.* 2022;28:4983–94. [DOI] [PubMed]
90. Xu W, Puligandla M, Halbert B, Haas NB, Flaherty KT, Uzzo RG, et al. Plasma KIM-1 Is Associated with Recurrence Risk after Nephrectomy for Localized Renal Cell Carcinoma: A Trial of the ECOG-ACRIN Research Group (E2805). *Clin Cancer Res.* 2021;27:3397–403. [DOI] [PubMed] [PMC]
91. Albiges L, Bex A, Suárez C, Uzzo R, Tang X, Assaf Z, et al. Circulating kidney injury molecule-1 (KIM-1) biomarker analysis in IMmotion010: A randomized phase 3 study of adjuvant (adj) atezolizumab (atezo) vs placebo (pbo) in patients (pts) with renal cell carcinoma (RCC) at increased risk of recurrence after resection. *JCO.* 2024;42:4506. [DOI]
92. Lucarelli G, Rutigliano M, Loizzo D, di Meo NA, Lasorsa F, Mastropasqua M, et al. MUC1 Tissue Expression and Its Soluble Form CA15-3 Identify a Clear Cell Renal Cell Carcinoma with Distinct Metabolic Profile and Poor Clinical Outcome. *Int J Mol Sci.* 2022;23:13968. [DOI] [PubMed] [PMC]
93. Zhou Y, Tao L, Qiu J, Xu J, Yang X, Zhang Y, et al. Tumor biomarkers for diagnosis, prognosis and targeted therapy. *Signal Transduct Target Ther.* 2024;9:132. [DOI] [PubMed] [PMC]
94. Mamdani H, Ahmed S, Armstrong S, Mok T, Jalal SI. Blood-based tumor biomarkers in lung cancer for detection and treatment. *Transl Lung Cancer Res.* 2017;6:648–60. [DOI] [PubMed] [PMC]
95. Zhang L, Riethdorf S, Wu G, Wang T, Yang K, Peng G, et al. Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. *Clin Cancer Res.* 2012;18:5701–10. [DOI] [PubMed]
96. Han L, Chen W, Zhao Q. Prognostic value of circulating tumor cells in patients with pancreatic cancer: a meta-analysis. *Tumour Biol.* 2014;35:2473–80. [DOI] [PubMed]
97. Ma X, Xiao Z, Li X, Wang F, Zhang J, Zhou R, et al. Prognostic role of circulating tumor cells and disseminated tumor cells in patients with prostate cancer: a systematic review and meta-analysis. *Tumour Biol.* 2014;35:5551–60. [DOI] [PubMed]
98. Wang S, Zheng G, Cheng B, Chen F, Wang Z, Chen Y, et al. Circulating tumor cells (CTCs) detected by RT-PCR and its prognostic role in gastric cancer: a meta-analysis of published literature. *PLoS One.* 2014;9:e99259. [DOI] [PubMed] [PMC]
99. Karachaliou N, Mayo-de-Las-Casas C, Molina-Vila MA, Rosell R. Real-time liquid biopsies become a reality in cancer treatment. *Ann Transl Med.* 2015;3:36. [DOI] [PubMed] [PMC]
100. Cao L, Yang W, Zhao X, Chen Z. Diagnostic and prognostic value of circulating tumor cells in renal cell cancer: A systematic review and meta-analysis. *Asian J Surg.* 2024;47:3425–34. [DOI] [PubMed]
101. Smit DJ, Pantel K. Circulating tumor cells as liquid biopsy markers in cancer patients. *Mol Aspects Med.* 2024;96:101258. [DOI] [PubMed]
102. Song J, Yu Z, Dong B, Zhu M, Guo X, Ma Y, et al. Clinical significance of circulating tumour cells and Ki-67 in renal cell carcinoma. *World J Surg Oncol.* 2021;19:156. [DOI] [PubMed] [PMC]
103. Guan Y, Xu F, Tian J, Wang Y, Guo N, Wan Z, et al. Prognostic value of circulating tumor cells and immune-inflammatory cells in patients with renal cell carcinoma. *Urol Oncol.* 2022;40:167.e21–32. [DOI] [PubMed]
104. Wang Q, Li Z, Zhai W, Zheng J. Clinical values of circulating tumor cells count in localized renal cell carcinoma. *Transl Cancer Res.* 2023;12:2351–60. [DOI] [PubMed] [PMC]

105. Basso U, Facchinetti A, Rossi E, Maruzzo M, Conteduca V, Aieta M, et al. Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial. *Oncologist*. 2021;26:740–50. [DOI] [PubMed] [PMC]
106. Bootsma M, McKay RR, Emamekhoo H, Bade RM, Schehr JL, Mannino MC, et al. Longitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma. *J Clin Oncol*. 2022; 40:3633–41. [DOI] [PubMed] [PMC]
107. Kim H, Park KU. Clinical Circulating Tumor DNA Testing for Precision Oncology. *Cancer Res Treat*. 2023;55:351–66. [DOI] [PubMed] [PMC]
108. Feng G, Ye X, Fang F, Pu C, Huang H, Li G. Quantification of plasma cell-free DNA in predicting therapeutic efficacy of sorafenib on metastatic clear cell renal cell carcinoma. *Dis Markers*. 2013;34: 105–11. [DOI] [PubMed] [PMC]
109. Skrypkinia I, Tsyba L, Onyshchenko K, Morderer D, Kashparova O, Nikolaenko O, et al. Concentration and Methylation of Cell-Free DNA from Blood Plasma as Diagnostic Markers of Renal Cancer. *Dis Markers*. 2016;2016:3693096. [DOI] [PubMed] [PMC]
110. de Martino M, Klatte T, Haitel A, Marberger M. Serum cell-free DNA in renal cell carcinoma: a diagnostic and prognostic marker. *Cancer*. 2012;118:82–90. [DOI] [PubMed]
111. Lasseter K, Nassar AH, Hamieh L, Berchuck JE, Nuzzo PV, Korthauer K, et al. Plasma cell-free DNA variant analysis compared with methylated DNA analysis in renal cell carcinoma. *Genet Med*. 2020; 22:1366–73. [DOI] [PubMed]
112. Geertsen L, Koldby KM, Thomassen M, Kruse T, Lund L. Circulating Tumor DNA in Patients with Renal Cell Carcinoma. A Systematic Review of the Literature. *Eur Urol Open Sci*. 2022;37:27–35. [DOI] [PubMed] [PMC]
113. Zill OA, Banks KC, Fairclough SR, Mortimer SA, Vowles JV, Mokhtari R, et al. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients. *Clin Cancer Res*. 2018;24:3528–38. [DOI] [PubMed]
114. Park JS, Kim H, Jang WS, Kim J, Ham WS, Lee ST. ctDNA predicts clinical T1a to pathological T3a upstaging after partial nephrectomy. *Cancer Sci*. 2024;115:1680–7. [DOI] [PubMed] [PMC]
115. Smigelski M, Sudhaman S, Nagpal S, Brooks B, Gerald T, Sanchez-Mendez R, et al. 1908P Utility of circulating tumor (ct)DNA testing for molecular residual disease (MRD) detection and treatment response monitoring in patients (pts) with renal cell carcinoma (RCC). *Ann Oncol*. 2023;34:S1027. [DOI]
116. Lu H, Busch J, Jung M, Rabenhorst S, Ralla B, Kilic E, et al. Diagnostic and prognostic potential of circulating cell-free genomic and mitochondrial DNA fragments in clear cell renal cell carcinoma patients. *Clin Chim Acta*. 2016;452:109–19. [DOI] [PubMed]
117. Yamamoto Y, Uemura M, Fujita M, Maejima K, Koh Y, Matsushita M, et al. Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma. *Cancer Sci*. 2019;110:617–28. [DOI] [PubMed] [PMC]
118. Kotecha RR, Gedvilaite E, Ptashkin R, Knezevic A, Murray S, Johnson I, et al. Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma. *JCO Precis Oncol*. 2022;6:e2200012. [DOI] [PubMed] [PMC]
119. Maia MC, Bergerot PG, Dizman N, Hsu J, Jones J, Lanman RB, et al. Association of Circulating Tumor DNA (ctDNA) Detection in Metastatic Renal Cell Carcinoma (mRCC) with Tumor Burden. *Kidney Cancer*. 2017;1:65–70. [DOI] [PubMed] [PMC]
120. Chehrazi-Raffle A, Muddasani R, Dizman N, Hsu J, Meza L, Zengin ZB, et al. Ultrasensitive Circulating Tumor DNA Pilot Study Distinguishes Complete Response and Partial Response With Immunotherapy in Patients With Metastatic Renal Cell Carcinoma. *JCO Precis Oncol*. 2023;7: e2200543. [DOI] [PubMed] [PMC]
121. Ludwig N, Leidinger P, Becker K, Backes C, Fehlmann T, Pallasch C, et al. Distribution of miRNA expression across human tissues. *Nucleic Acids Res*. 2016;44:3865–77. [DOI] [PubMed] [PMC]

122. Huang G, Li H, Wang J, Peng X, Liu K, Zhao L, et al. Combination of tumor suppressor miR-20b-5p, miR-30a-5p, and miR-196a-5p as a serum diagnostic panel for renal cell carcinoma. *Pathol Res Pract*. 2020;216:153152. [DOI] [PubMed]
123. Huang G, Li X, Chen Z, Wang J, Zhang C, Chen X, et al. A Three-microRNA Panel in Serum: Serving as a Potential Diagnostic Biomarker for Renal Cell Carcinoma. *Pathol Oncol Res*. 2020;26:2425–34. [DOI] [PubMed]
124. Chen X, Li R, Li X, Peng X, Zhang C, Liu K, et al. Identification of a four-microRNA panel in serum for screening renal cell carcinoma. *Pathol Res Pract*. 2021;227:153625. [DOI] [PubMed]
125. Cinque A, Vago R, Trevisani F. Circulating RNA in Kidney Cancer: What We Know and What We Still Suppose. *Genes (Basel)*. 2021;12:835. [DOI] [PubMed] [PMC]
126. Soleimani M, Thi M, Janfaza S, Ozcan G, Mazurek S, Ozgun G, et al. Circulating microRNA-155-3p levels predicts response to first line immunotherapy in patients with metastatic renal cell carcinoma. *Sci Rep*. 2024;14:8603. [DOI] [PubMed] [PMC]
127. Huber V, Vallacchi V, Fleming V, Hu X, Cova A, Dugo M, et al. Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma. *J Clin Invest*. 2018;128:5505–16. [DOI] [PubMed] [PMC]
128. Martinez-Usatorre A, Sempere LF, Carmona SJ, Carretero-Iglesia L, Monnot G, Speiser DE, et al. MicroRNA-155 Expression Is Enhanced by T-cell Receptor Stimulation Strength and Correlates with Improved Tumor Control in Melanoma. *Cancer Immunol Res*. 2019;7:1013–24. [DOI] [PubMed]
129. Li R, Chen W, Lu C, Li X, Chen X, Huang G, et al. A four-microRNA panel in serum may serve as potential biomarker for renal cell carcinoma diagnosis. *Front Oncol*. 2023;12:1076303. [DOI] [PubMed] [PMC]
130. Teng G, Hakimpour P, Landgraf P, Rice A, Tuschl T, Casellas R, et al. MicroRNA-155 is a negative regulator of activation-induced cytidine deaminase. *Immunity*. 2008;28:621–9. [DOI] [PubMed] [PMC]
131. Labadie BW, Bao R, Luke JJ. Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis. *Clin Cancer Res*. 2019;25:1462–71. [DOI] [PubMed] [PMC]
132. Uyttenhove C, Pilotte L, Théate I, Stroobant V, Colau D, Parmentier N, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. *Nat Med*. 2003;9:1269–74. [DOI] [PubMed]
133. Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. *J Exp Med*. 2013;210:1389–402. [DOI] [PubMed] [PMC]
134. Long GV, Dummer R, Hamid O, Gajewski TF, Caglevic C, Dalle S, et al. Epcadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. *Lancet Oncol*. 2019;20:1083–97. [DOI] [PubMed]
135. Li H, Bullock K, Gurjao C, Braun D, Shukla SA, Bossé D, et al. Metabolomic adaptations and correlates of survival to immune checkpoint blockade. *Nat Commun*. 2019;10:4346. [DOI] [PubMed] [PMC]
136. Ishihara H, Tachibana H, Takagi T, Kondo T, Fukuda H, Yoshida K, et al. Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma. *Target Oncol*. 2019;14:453–63. [DOI] [PubMed]
137. Suzuki K, Terakawa T, Furukawa J, Harada K, Hinata N, Nakano Y, et al. C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab. *Int J Clin Oncol*. 2020;25:135–44. [DOI] [PubMed]

138. Shirotake S, Takamatsu K, Mizuno R, Kaneko GO, Nishimoto K, Oya M, et al. Serum Lactate Dehydrogenase Before Nivolumab Treatment Could Be a Therapeutic Prognostic Biomarker for Patients With Metastatic Clear Cell Renal Cell Carcinoma. *Anticancer Res.* 2019;39:4371–7. [[DOI](#)] [[PubMed](#)]
139. Zhuang TZ, Ravindranathan D, Liu Y, Martini DJ, Brown JT, Nazha B, et al. Baseline Neutrophil-to-Eosinophil Ratio Is Associated with Outcomes in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. *Oncologist.* 2023;28:239–45. [[DOI](#)] [[PubMed](#)] [[PMC](#)]
140. Mauge L, Galy-Fauroux I, Elaidi RT, Ben Dhia L, Bertil S, Bennamoun M, et al. 686P Angiogenesis related blood biomarkers of response to checkpoint inhibitors (IO) and VEGFR-TKI in metastatic renal cell carcinoma (mRCC): Results from the BIONIKK prospective trial. *Ann Oncol.* 2021;32:S704. [[DOI](#)]